Bladder Cancer Matters

Fran Curtis: Fighting Bladder Cancer, Inspiring Others

Bladder Cancer Matters

Show Notes

Bladder cancer survivor Fran Curtis shares her powerful journey on Bladder Cancer Matters, discussing her experience with ADSTILADRIN® (nadofaragene firadenovec-vncg), the impact of early detection, and her advocacy work with BCAN. Diagnosed with non-muscle invasive bladder cancer after subtle urinary changes, Fran highlights the importance of listening to your body, seeking the best care, and finding hope through community support. Released during International Women's History Month, this episode underscores the need for gender equity in healthcare. Tune in to hear Fran's inspiring story and insights! IMPORTANT SAFETY INFORMATION Who should not receive ADSTILADRIN? Do not receive ADSTILADRIN if you have a sensitivity to interferon alfa or any of its components. What is the most important information I should know about ADSTILADRIN? Individuals who are immunosuppressed or immune-deficient should not prepare, administer, receive, or come into contact with ADSTILADRIN. What should I tell my healthcare provider? Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. What are the possible side effects of ADSTILADRIN? The most common side effects of ADSTILADRIN include: Urinary discharge, fatigue, bladder spasm, urgency to urinate, and blood in your urine. These are not all the possible side effects of ADSTILADRIN. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to FDA. Visit www.FDA.gov/medwatch or call 1-800-332-1088. You may also contact Ferring Pharmaceuticals at 1-888-FERRING. What other information should I know about using ADSTILADRIN? For 2 days following treatment, voided urine should be disinfected for 15 minutes with an equal volume of bleach before flushing. For more important information, call 1-888-337-7464. Please see full Prescribing Information.

More from Bladder Cancer Matters

Oct 19, 2026

Can patients with muscle-invasive bladder cancer safely keep their bladders after successful treatment? And does having "no evidence of disease" really mean the cancer is gone? In this episode of Bladder Cancer Matters, host and bladder cancer survivor Rick Bangs welcomes back renowned bladder cancer expert Dr. Ashish Kamat of MD Anderson Cancer Center to explore one of the most important decisions patients may face: bladder removal or bladder preservation. Dr. Kamat explains how newer treatments are improving survival, what doctors can—and cannot—determine about whether cancer remains and the potential risks and benefits of preserving the bladder. He also discusses why ongoing monitoring is essential and what patients should ask their medical teams before making treatment decisions. If you or someone you love is facing bladder cancer treatment, this conversation offers valuable insights to help you understand your options and make informed decisions.

Oct 5, 2026

Bladder cancer treatment can change much more than a person's physical health — it can profoundly affect sexuality, intimacy, body image and relationships. In this candid and informative episode of Bladder Cancer Matters, host and bladder cancer survivor Rick Bangs talks with Mary Dunn, a certified adult nurse practitioner about a topic patients and partners may find difficult to discuss: sex after bladder cancer. Mary explains how bladder cancer and its treatments can affect sexual health for both men and women, offers practical strategies for managing common challenges and reviews treatment options that can help. Just as importantly, she explores intimacy beyond sex and encourages patients to make sexual health part of the conversation with their healthcare teams. Listener discretion advised: This episode contains explicit language and frank discussions of sexual health, sexual function and anatomy that may not be appropriate for all listeners.

Aug 31, 2026

In this eye-opening episode of Bladder Cancer Matters, brought to you by the Bladder Cancer Advocacy Network, host Rick Bangs sits down with Todd Davey of Ferring Pharmaceuticals to pull back the curtain on something most patients never hear about: market access. What actually happens between a breakthrough therapy and the moment a patient can affordably receive it? Todd walks listeners through the strategy, value demonstration, and launch planning that determine whether innovative bladder cancer treatments—like ADSTILADRIN®—are covered by insurance and accessible without crushing out-of-pocket costs. It's a candid, behind-the-scenes look at how science, economics, and patient advocacy intersect—and why getting this right can mean fewer barriers, less financial stress, and more options for families facing bladder cancer. If you've ever wondered how new treatments move from the lab to real life, this episode will give you clarity—and a new appreciation for the complex work that helps turn innovation into access.

Aug 21, 2026

For women facing radical cystectomy, removing the bladder doesn't always have to mean removing reproductive organs as well. In this episode of Bladder Cancer Matters, host Rick Bangs talks with Cleveland Clinic urologic oncologist Dr. Rebecca Campbell about organ-sparing radical cystectomy and how, for carefully selected patients, surgeons may be able to preserve the vagina, uterus and ovaries while still prioritizing effective cancer treatment. Dr. Campbell explains who may be a candidate, how organ sparing can help protect sexual function, hormonal health, continence and overall quality of life and why women should feel empowered to ask their surgeon about their options—or seek a second opinion if those options aren't discussed. It's an important conversation about looking beyond bladder removal to the life a patient wants to live after treatment.

Jul 23, 2026

In this fascinating episode of Bladder Cancer Matters, host Rick Bangs sits down with renowned bladder cancer expert Dr. Robert Svatek to discuss how the field has been transformed over the past 15 years—and where it's headed next. Dr. Svatek reflects on his journey from academic surgeon and researcher to Vice President of Clinical Development at CG Oncology, sharing behind-the-scenes insights into clinical trials, emerging immunotherapies and the collaborative effort required to bring promising new treatments from the laboratory to patients. Whether you're a patient, caregiver, advocate or healthcare professional, this conversation offers an inspiring look at the remarkable progress being made in bladder cancer research while acknowledging the challenges that remain. You'll also hear how patient participation in clinical trials is driving innovation and why experts are more optimistic than ever about the future of bladder cancer care.

See all episodes →